PMID- 35586608
OWN - NLM
STAT- MEDLINE
DCOM- 20220520
LR  - 20220727
IS  - 2291-2797 (Electronic)
IS  - 2291-2789 (Print)
IS  - 2291-2789 (Linking)
VI  - 2022
DP  - 2022
TI  - Efficacy and Safety of the Combination of Transarterial Chemoembolization with 
      Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective 
      Study of 38 Patients from a Single Center.
PG  - 7982118
LID - 10.1155/2022/7982118 [doi]
LID - 7982118
AB  - OBJECTIVE: To evaluate the effectiveness and safety of transarterial 
      chemoembolization (TACE) combined with immune checkpoint inhibition 
      (camrelizumab) plus an antiangiogenic agent (apatinib) for advanced 
      hepatocellular carcinoma (HCC). METHODS: Between March 2019 and April 2021, the 
      clinical data of 38 patients diagnosed with advanced HCC who initially received 
      TACE combined with camrelizumab plus apatinib were reviewed retrospectively. The 
      objective response rate (ORR) and disease control rate (DCR) according to 
      modified response evaluation criteria in solid tumors, progression-free survival 
      (PFS), overall survival (OS), and adverse events (AEs) were evaluated. RESULTS: 
      At 2-3 months after initial therapy, the ORR and DCR was 50.0% (19/38) and 76.3% 
      (29/38), respectively. The median PFS and OS were 7.3 months (range: 1.0-22.6 
      months) and 13.5 months (range: 2.3-24.3 months), respectively. Treatment-related 
      AEs (grades 3-4) were observed in 25 patients (67.8%). No treatment-related 
      deaths occurred. CONCLUSION: The combination of TACE with camrelizumab plus 
      apatinib for the treatment of patients with advanced HCC showed promising 
      efficacy and a manageable safety profile.
CI  - Copyright (c) 2022 Jin-Xing Zhang et al.
FAU - Zhang, Jin-Xing
AU  - Zhang JX
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing 210029, China.
FAU - Chen, Yu-Xing
AU  - Chen YX
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing 210029, China.
FAU - Zhou, Chun-Gao
AU  - Zhou CG
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing 210029, China.
FAU - Liu, Jin
AU  - Liu J
AD  - Department of Clinical Medicine Research Institution, The First Affiliated 
      Hospital with Nanjing Medical University, Nanjing 210029, China.
FAU - Liu, Sheng
AU  - Liu S
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing 210029, China.
FAU - Shi, Hai-Bin
AU  - Shi HB
AUID- ORCID: 0000-0003-1293-5789
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing 210029, China.
FAU - Zu, Qing-Quan
AU  - Zu QQ
AUID- ORCID: 0000-0001-7359-0791
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing 210029, China.
LA  - eng
PT  - Journal Article
DEP - 20220509
PL  - Egypt
TA  - Can J Gastroenterol Hepatol
JT  - Canadian journal of gastroenterology & hepatology
JID - 101623613
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
RN  - 73096E137E (camrelizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - *Carcinoma, Hepatocellular/drug therapy/pathology
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - Humans
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - Pyridines
MH  - Retrospective Studies
PMC - PMC9110252
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/05/20 06:00
MHDA- 2022/05/21 06:00
PMCR- 2022/05/09
CRDT- 2022/05/19 02:28
PHST- 2022/03/05 00:00 [received]
PHST- 2022/04/17 00:00 [revised]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2022/05/19 02:28 [entrez]
PHST- 2022/05/20 06:00 [pubmed]
PHST- 2022/05/21 06:00 [medline]
PHST- 2022/05/09 00:00 [pmc-release]
AID - 10.1155/2022/7982118 [doi]
PST - epublish
SO  - Can J Gastroenterol Hepatol. 2022 May 9;2022:7982118. doi: 10.1155/2022/7982118. 
      eCollection 2022.